COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus

Int J Dermatol. 2020 Nov;59(11):1423-1424. doi: 10.1111/ijd.15209. Epub 2020 Sep 23.

Authors

Andrea Chiricozzi^{1

2}, Simone Garcovich^{1

2}, Dalma Malvaso^{1

2}, Giulia Giovanardi^{1

2}, Ketty Peris^{1

2}

Affiliations

¹ Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
² Dermatologia, Università Cattolica del Sacro Cuore, Rome, Italy.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Anti-Bacterial Agents / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use*
Antiphospholipid Syndrome / complications
Antiphospholipid Syndrome / drug therapy
Antirheumatic Agents / therapeutic use
Azithromycin / therapeutic use
COVID-19 / complications*
COVID-19 Drug Treatment
Dermatologic Agents / therapeutic use*
Female
Hidradenitis Suppurativa / complications
Hidradenitis Suppurativa / drug therapy*
Humans
Hydroxychloroquine / therapeutic use
Lupus Erythematosus, Systemic / complications
Lupus Erythematosus, Systemic / drug therapy
SARS-CoV-2

Substances

Anti-Bacterial Agents
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Dermatologic Agents
Hydroxychloroquine
Azithromycin
secukinumab